Rheumatoid Arthritis - Pipeline Review, H2 2015

Rheumatoid Arthritis - Pipeline Review, H2 2015

Code: GMDHC7298IDB | Published: Dec-2015 | Pages: 1175 | Global Markets Direct
Price :

* Required Fields



Rheumatoid Arthritis - Pipeline Review, H2 2015


Global Markets Directs, Rheumatoid Arthritis - Pipeline Review, H2 2015, provides an overview of the Rheumatoid Arthritiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
3SBio Inc.
4D Pharma Plc
AB Science SA
AB2 Bio Ltd.
AbbVie Inc.
Ablynx NV
ACEA Biosciences, Inc.
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aegera Therapeutics Inc.
Alder Biopharmaceuticals Inc.
AlphaMab Co., Ltd
Amgen Inc.
Amura Holdings Limited
Aprogen, Inc.
Arena Pharmaceuticals, Inc.
arGentis Pharmaceuticals, LLC
Arrien Pharmaceuticals, LLC
Arthrogen BV
Asahi Kasei Pharma Corp.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
Avesthagen Limited
Avexxin AS
Axxam SpA
Bio-Cancer Treatment International Limited
Biocon Limited
Biokine Therapeutics Ltd.
BioLingus AG
Bionovis SA
BioTherapeutics Inc.
Bird Rock Bio, Inc.
Boehringer Ingelheim GmbH
Bone Medical Limited
Boryung Pharmaceutical Co., Ltd.
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Cardax Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc.
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Celltrion, Inc.
Cellworks Group, Inc.
ChemoCentryx, Inc.
Chipscreen Biosciences Ltd
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
CLL Pharma
Coherus BioSciences, Inc.
Commence Bio, Inc.
Compugen Ltd.
Confluence Life Sciences, Inc.
CrystalGenomics, Inc.
Cyclacel Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Dr. Reddys Laboratories Limited
Effimune SAS
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
Enceladus Pharmaceuticals BV
Endocyte, Inc.
Ensemble Therapeutics Corporation
Ensol Biosciences Inc.
Enzene Biosciences Ltd.
Epirus Biopharmaceuticals, Inc.
Exicure, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Fountain Biopharma Inc.
Galapagos NV
Genentech, Inc.
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Griffin Discoveries BV
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hansa Medical AB
Hanwha Chemical Corporation
HEC Pharm Co., Ltd.
Hetero Drugs Limited
Hospira, Inc.
Huabo Biopharm Co., Ltd.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
Immune Response BioPharma, Inc.
ImmunoFrontier, Inc.
Inbiopro Solutions Pvt. Ltd.
Innate Pharma SA
Innovent Biologics, Inc.
Intas Pharmaceuticals Ltd.
Invion Limited
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Jyant Technologies, Inc.
Kadmon Corporation, LLC
KAHR medical Ltd.
Karus Therapeutics Limited
Kezar Life Sciences, Inc.
Kineta, Inc.
Lead Pharma Holding B.V.
LG Life Science LTD.
Lipocure Ltd.
Lupin Limited
Mabion SA
Mabtech Limited
mAbxience S.A.
MacroGenics, Inc.
Mebiopharm Co., Ltd.
MedAnnex Ltd
MediGene AG
MedImmune, LLC
Merck & Co., Inc.
Mertiva AB
Mesoblast Limited
MetrioPharm AG
Mitsubishi Tanabe Pharma Corporation
Modern Biosciences Plc
ModiQuest B.V.
Momenta Pharmaceuticals, Inc.
Morphotek, Inc.
Mycenax Biotech Inc.
Myos Corporation
Myungmoon pharmaceutical Co.,Ltd.
NanoSmart Pharmaceuticals, Inc.
Navigen Pharmaceuticals, Inc.
Neovacs SA
Nichi-Iko Pharmaceutical Co., Ltd.
Nimbus Therapeutics, LLC
Novartis AG
NovImmune SA
Nuevolution A/S
Nuvo Research Inc.
Omeros Corporation
Oncobiologics, Inc.
OncoImmune, Inc.
OPKO Health, Inc.
Opsona Therapeutics Limited
Orchid Chemicals & Pharmaceuticals Ltd
Oscotec Inc.
Padlock Therapeutics, Inc.
Panacea Biotec Limited
Paras Biopharmaceuticals Finland Oy
Peptinnovate Limited
Peptinov SAS
Pfenex Inc.
Pfizer Inc.
Pharmacyclics, Inc.
PharmaIN Corporation
Pharmedartis GmbH
Phenex Pharmaceuticals AG
Philogen S.p.A.
Principia Biopharma Inc.
Progenra, Inc.
ProNoxis AB
ProtAb Ltd
Protagonist Therapeutics Inc.
Protalex, Inc.
Protalix BioTherapeutics, Inc.
Provid Pharmaceuticals, Inc.
Qu Biologics Inc.
Re-Pharm Limited
ReceptoPharm, Inc.
RedHill Biopharma Ltd.
Redx Pharma Plc
Regeneron Pharmaceuticals, Inc.
Resverlogix Corp.
ReveraGen BioPharma, Inc.
Rhizen Pharmaceuticals S.A.
Richter Gedeon Nyrt.
Rottapharm SpA
Salix Pharmaceuticals Ltd.
Sandoz International GmbH
Sareum Holdings Plc
SBI Biotech Co., Ltd.
Selvita SA
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Henlius Biotech Co., Ltd.
Shanghai Pharmaceutical Co., Ltd.
Swedish Orphan Biovitrum AB
Synovo GmbH
Syntrix Biosystems, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Company Limited
TechnoPhage SA
Teijin Pharma Limited
The International Biotechnology Center (IBC) Generium
Therapeutic Proteins International, LLC
TiGenix NV
Toleranzia AB
Tumorend, LLC
TxCell SA
U.S. Stem Cell, Inc.
ugichem GmbH
Unizyme Laboratories A/S
Vaccinex, Inc.
Vichem Chemie Research Ltd.
Vicore Pharma AB
Vida Therapeutics Inc.
Vitae Pharmaceuticals, Inc.
Vivia Biotech, S.L.
Xbrane Bioscience AB
Xencor, Inc.
XTL Biopharmaceuticals Ltd.
Yuhan Corporation
Yungjin Pharm. Co., Ltd.
Yuyu Pharma, Inc.
Zenyaku Kogyo Co., Ltd.
Zydus Cadila Healthcare Limited

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients